IL160371A0 - A new extended release oral dosage form - Google Patents

A new extended release oral dosage form

Info

Publication number
IL160371A0
IL160371A0 IL16037102A IL16037102A IL160371A0 IL 160371 A0 IL160371 A0 IL 160371A0 IL 16037102 A IL16037102 A IL 16037102A IL 16037102 A IL16037102 A IL 16037102A IL 160371 A0 IL160371 A0 IL 160371A0
Authority
IL
Israel
Prior art keywords
dosage form
oral dosage
extended release
release oral
new extended
Prior art date
Application number
IL16037102A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL160371A0 publication Critical patent/IL160371A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
IL16037102A 2001-08-29 2002-08-28 A new extended release oral dosage form IL160371A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0102887A SE0102887D0 (sv) 2001-08-29 2001-08-29 New formulation
PCT/SE2002/001541 WO2003017983A1 (fr) 2001-08-29 2002-08-28 Nouvelle forme posologique orale a liberation prolongee

Publications (1)

Publication Number Publication Date
IL160371A0 true IL160371A0 (en) 2004-07-25

Family

ID=20285178

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16037102A IL160371A0 (en) 2001-08-29 2002-08-28 A new extended release oral dosage form

Country Status (14)

Country Link
US (1) US20040197404A1 (fr)
EP (1) EP1423099A1 (fr)
JP (1) JP2005504052A (fr)
KR (1) KR20040032977A (fr)
CN (1) CN1549705A (fr)
BR (1) BR0212167A (fr)
CA (1) CA2457341A1 (fr)
HU (1) HUP0401599A3 (fr)
IL (1) IL160371A0 (fr)
MX (1) MXPA04001805A (fr)
NO (1) NO20040857L (fr)
SE (1) SE0102887D0 (fr)
WO (1) WO2003017983A1 (fr)
ZA (1) ZA200401547B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1904067B2 (fr) * 2004-12-03 2017-10-11 Merck Sharp & Dohme Corp. Formulation pharmaceutique de derives de carboxamide , inhibiteurs de l'hiv integrase, comprenant une composition a liberation contrôlee
EP1946780B1 (fr) 2005-11-11 2012-01-11 Asahi Kasei Chemicals Corporation Preparation solide a liberation controlee
GB0616794D0 (en) * 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
US20100069390A1 (en) 2008-09-05 2010-03-18 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (ADHD)
AU2012336036A1 (en) * 2011-11-07 2014-06-19 Diakron Pharmaceuticals Inc. An extended release formulation of a direct thrombin inhibitor
US9358204B2 (en) * 2012-02-08 2016-06-07 Supernus Pharmaceuticals, Inc. Formulations of viloxazine
EP2822542A1 (fr) * 2012-03-07 2015-01-14 Santarus, Inc. Formes posologiques solides à libération contrôlée de mésalamine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
US4837032A (en) * 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
GB8624213D0 (en) * 1986-10-09 1986-11-12 Sandoz Canada Inc Sustained release pharmaceutical compositions
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
SE510305C2 (sv) * 1997-05-30 1999-05-10 Astra Ab Nytt salt
AR035642A1 (es) * 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor

Also Published As

Publication number Publication date
MXPA04001805A (es) 2004-07-08
ZA200401547B (en) 2004-11-17
HUP0401599A2 (hu) 2004-11-29
WO2003017983A1 (fr) 2003-03-06
US20040197404A1 (en) 2004-10-07
CN1549705A (zh) 2004-11-24
HUP0401599A3 (en) 2007-03-28
EP1423099A1 (fr) 2004-06-02
SE0102887D0 (sv) 2001-08-29
KR20040032977A (ko) 2004-04-17
BR0212167A (pt) 2004-07-20
NO20040857L (no) 2004-04-19
JP2005504052A (ja) 2005-02-10
CA2457341A1 (fr) 2003-03-06

Similar Documents

Publication Publication Date Title
EG23943A (en) Flash-melt oral dosage formulation
EP1553925A4 (fr) Forme posologique orale a liberation modifiee
HUP0203204A3 (en) Oral dosage forms
AU146752S (en) A handpiece
AU6089200A (en) Rapid immediate release oral dosage form
HK1090840A1 (en) Extended release oral dosage composition
HUP0301697A3 (en) Oral solid dose vaccine
GB2383989B (en) Improved oral medicine dispenser
IL161143A0 (en) A flash-melt pharmaceutical oral dosage composition
IL160371A0 (en) A new extended release oral dosage form
EP1357898A4 (fr) Forme posologique orale a liberation regulee amelioree
AU2003283937A1 (en) A new oral immediated release dosage form
HUP0401587A3 (en) A new extended release oral dosage form
AU2002313628A1 (en) Tamper resistant oral dosage form
AU2002327993A1 (en) A new extended release oral dosage form
GB0014497D0 (en) Oral dosage form
HU0900677D0 (en) Extended release oral dosage composition
AU2001293278A1 (en) Tableted oral extended release dosage form
HK1047232A1 (zh) 口服劑型
PL341178A1 (en) Oral pharmaceutical dosage forms
GB9925069D0 (en) Oral dosage form
AU149689S (en) A napkin
PL373799A1 (en) Flashmelt oral dosage formulation
GB0127024D0 (en) Medicinal compounds
GB0126997D0 (en) Medicinal Compounds